IO Biotech, Inc. (IOBT)

USD 0.77

(0.84%)

Market Cap (In USD)

50.43 Million

Revenue (In USD)

-

Net Income (In USD)

-86.08 Million

Avg. Volume

442.65 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.66-2.098
PE
-
EPS
-
Beta Value
0.419
ISIN
US4497781090
CUSIP
449778109
CIK
1865494
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mai-Britt Zocca Ph.D.
Employee Count
-
Website
https://www.iobiotech.com
Ipo Date
2021-11-05
Details
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.